AllianceBernstein’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-399,290
Closed -$27.2M 3381
2022
Q3
$27.2M Buy
399,290
+326,790
+451% +$18M 0.01% 736
2022
Q2
$2.32M Buy
72,500
+798
+1% +$23.4K ﹤0.01% 1859
2022
Q1
$2.48M Buy
71,702
+200
+0.3% +$5.98K ﹤0.01% 1958
2021
Q4
$2.09M Sell
71,502
-1,100
-2% -$34.1K ﹤0.01% 2120
2021
Q3
$1.85M Hold
72,602
﹤0.01% 2215
2021
Q2
$2.54M Buy
72,602
+45,267
+166% +$1.77M ﹤0.01% 2045
2021
Q1
$1.11M Sell
27,335
-10,302
-27% -$474K ﹤0.01% 2366
2020
Q4
$1.63M Sell
37,637
-154
-0.4% -$7.59K ﹤0.01% 2098
2020
Q3
$2.08M Sell
37,791
-6,393
-14% -$406K ﹤0.01% 1825
2020
Q2
$2.79M Sell
44,184
-83,716
-65% -$5.74M ﹤0.01% 1652
2020
Q1
$6.53M Buy
127,900
+1,100
+0.9% +$73.7K ﹤0.01% 1068
2019
Q4
$10.1M Buy
126,800
+45,300
+56% +$2.68M 0.01% 1088
2019
Q3
$3.95M Hold
81,500
﹤0.01% 1545
2019
Q2
$4.29M Buy
81,500
+7,300
+10% +$420K ﹤0.01% 1516
2019
Q1
$3.93M Buy
74,200
+900
+1% +$44.2K ﹤0.01% 1506
2018
Q4
$3.01M Hold
73,300
﹤0.01% 1594
2018
Q3
$2.79M Buy
73,300
+900
+1% +$39.9K ﹤0.01% 1708
2018
Q2
$3.27M Buy
72,400
+16,900
+30% +$770K ﹤0.01% 1564
2018
Q1
$2.68M Buy
55,500
+300
+0.5% +$16.7K ﹤0.01% 1630
2017
Q4
$2.17M Sell
55,200
-20,000
-27% -$747K ﹤0.01% 1797
2017
Q3
$2.33M Sell
75,200
-30,000
-29% -$844K ﹤0.01% 1744
2017
Q2
$2.88M Buy
105,200
+81,500
+344% +$2.43M ﹤0.01% 1577
2017
Q1
$873K Sell
23,700
-4,800
-17% -$121K ﹤0.01% 2308
2016
Q4
$412K Hold
28,500
﹤0.01% 2627
2016
Q3
$657K Buy
28,500
+2,954
+12% +$56.3K ﹤0.01% 2416
2016
Q2
$424K Buy
+25,546
New +$515K ﹤0.01% 2572
2016
Q1
Sell
-26,416
Closed -$854K 2942
2015
Q4
$854K Buy
26,416
+8,900
+51% +$385K ﹤0.01% 2215
2015
Q3
$738K Buy
+17,516
New +$826K ﹤0.01% 2315

Other funds holding GBT

AllianceBernstein's GBT Position: Q4 2022 in Review

AllianceBernstein sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 399,290 shares — an estimated $27.2M sold.

AllianceBernstein first reported a position in GBT in Q3 2015 and held it in 28 quarters. The position peaked at $27.2M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • AllianceBernstein reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • AllianceBernstein sold 399,290 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $27.2M.
  • AllianceBernstein first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 28 quarters.
  • AllianceBernstein's Global Blood Therapeutics, Inc. position peaked at $27.2M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on AllianceBernstein's 13F filing for Q4 2022, filed 15 Feb 2023.